Therapeutic Indications

Cemiplimab is indicated for:

Metastatic or locally advanced cutaneous squamous cell carcinoma

Irrespective of gender only Adults (18 years old or older)

Cemiplimab as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 350 mg once every 3 weeks